Table III.

Expected peak and trough levels at steady state reported for each direct oral anticoagulant by the technical annexes issued by the European Medical Agency for dabigatran, rivaroxaban and apixaban³⁷–³⁹ or by the literature for edoxaban⁴⁰.

Drug and dose (mg)	Peak (ng/mL)		Trough (ng/mL)
	Mean	Range	Mean	Range
Dabigatran 150	175	117–275	91	61–143
Rivaroxaban 20	215	22–535	32	6–239
Apixaban for prevention of VTE: elective hip or knee replacement
2.5 b.d.	77	41–146	51	23–109
Apixaban for prevention of stroke and systemic embolism
2.5 b.d.	123	69–221	79	34–162
5 b.d.	171	91–321	103	41–230
Apixaban for treatment of DVT, treatment of PE and prevention of recurrent DVT and PE
2.5 b.d.	67	30–153	32	11–90
5 b.d.	132	59–302	63	22–177
10 b.d.	251	111–572	120	41–335
Edoxaban 30	n.a.	n.a.	27	15–45
Edoxaban 60	n.a.	n.a.	36	19–62

VTE: venous thromboembolism; DVT: deep vein thrombosis; PE: pulmonary embolism; n.a.: not available; b.d.: twice daily.